MissionIRNewsBreaks – Youngevity International Inc.’s (NASDAQ: YGYI) Khrysos Industries Leases State- of-the-Art, Florida Based Hemp Processing and Manufacturing Facility

Youngevity International (NASDAQ: YGYI), a leading multi-channel lifestyle company operating in three distinct business segments, through its wholly owned subsidiary, Khrysos Industries, Inc., today announced that it has leased 82,000 square feet in Orlando, Florida to house its facility for post processing hemp derived products and finished goods manufacturing.  The state-of-the-art facility features a 46,200 square foot production area and is the former home of Nephron Pharmaceuticals GMP Certified sterile manufacturing operations. “We believe this facility provides us the opportunity to accelerate our post processing and manufacturing capabilities by approximately two years in terms of production output.  The amenities and the infrastructure within the facility saves us significant CAPEX expense, and, more importantly, provides us the ability to grow more rapidly to meet market demand,” Khrysos President Dwayne Dundore, PhD, said in the news release.  “We are in the process of moving over our post processing equipment and the extensive power systems in this facility allows us to scale as needed.  We expect post processing to be up and running in September and we will then set up our finished product manufacturing lines.”

To view the full press release, visit http://ibn.fm/xI5l9

About Youngevity International Inc.

Youngevity International Inc. is a multi-channel lifestyle company operating in three distinct business segments, including a commercial coffee enterprise, a commercial hemp enterprise and a multi-vertical omni direct selling enterprise. The company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity; YGYI offers products from the six top-selling retail categories, including health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry and innovative services. For more information, visit the company’s website at www.YGYI.com

NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://ibn.fm/YGYI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Canopy Rivers Inc.’s (TSX.V: RIV) (OTC: CNPOF) Headset Launches Cannabis Market Intelligence Tool in Canada

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) this morning announced that its portfolio company, Headset, Inc., has launched its competitive cannabis market intelligence tool in Canada. Headset Insights is already trusted by hundreds of operators in numerous U.S. markets and provides users with real-time market data to help uncover strategic opportunities, monitor consumer trends and behaviors, and keep tabs on competitors. “This announcement from Headset is a testament to the company’s rapid growth since being backed by RIV and joining our ecosystem in January 2019,” Canopy Rivers President and CEO Narbe Alexandrian said in the news release. “We believe that Headset Insights is an unmatched resource for retailers, including Canopy Rivers portfolio company YSS, empowering them to make data-driven decisions based on trends unique to the Canadian market.”

To view the full press release, visit http://ibn.fm/F6Rat

About Canopy Rivers Inc.

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers works collaboratively with Canopy Growth Corporation (TSX: WEED, NYSE: CGC) to identify strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem. For more information, visit the company’s website at www.CanopyRivers.com.

NOTE TO INVESTORS: The latest news and updates relating to CNPOF are available in the company’s newsroom at http://ibn.fm/CNPOF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – INmune Bio Inc. (NASDAQ: INMB) Advances Clinical Development of INB03

INmune Bio (NASDAQ: INMB) co-founder and CEO Dr. RJ Tesi recently reported positive preliminary data from the company’s INB03 Phase I clinical trial in cancer patients during a presentation at Cambridge Healthtech Institute’s 7th Annual Immuno-Oncology Summit in Boston (http://ibn.fm/m1Iy3). An article discussing the company reads, “‘The goal of the Phase I study is to determine, in order of priority, the safety of INB03 in cancer patients, the dose of INB03 to take into the Phase II trials in cancer, and evidence of a biologic effect of INB03,’ stated Tesi, who is also INmune Bio’s chief medical officer. ‘All of these goals have been met. Using data from this trial, we have begun planning a Phase II trial using INB03 as part of combination immunotherapy in patients with cancer.’ . . . The Phase I trial is an open-label, dose-escalation trial in patients with advanced solid tumors. Patients received INB03, a novel, second-generation soluble TNF (tumor necrosis factor) inhibitor that works by leveraging a dominant-negative technology. Positive preliminary data from the first two cohorts were released. That data will be followed by a final report later this year as the company advances the program into a Phase II study.”

To view the full article, visit http://ibn.fm/Yv3yZ

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company developing therapies targeting the innate immune system to fight disease. INmune Bio is developing three product platforms: two products that reengineer the patient’s innate immune system’s response to cancer and one product to treat neuroinflammation that is currently focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell therapeutic that primes the patient’s NK cells to attack minimal residual disease, the remaining cancer cells that are difficult to detect, which often cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which often cause resistance to immunotherapy, such as anti-PD-1 checkpoint inhibitors. XPro1595 targets neuroinflammation, which causes microglial activation and neuronal cell death. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.INmuneBio.com.

NOTE TO INVESTORS: The latest news and updates relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Receives 100% Organic Rating from Corporate Knights

The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a cannabis-focused research and development company, was recently named as one of the eco-friendliest cannabis firms in Canada. An article discussing the company reads, “Corporate Knights, a Toronto-based publication, gave TGOD a 100% organic rating and cited its projected million-square-foot, ecologically efficient greenhouse in Valleyfield, Quebec (scheduled to operate later this year on renewable hydropower), as being a key component in the company’s anticipated growth (http://ibn.fm/jOxuA). As the budding cannabis industry continues to evolve, issues of sustainability and growing ‘greener’ product are rising to the surface, and TGOD is currently one of only a handful of organic growers in Canada.”

To view the full article, visit http://ibn.fm/Bt6V9

About the Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman is a publicly traded, premium, global organic cannabis company with operations focused on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. TGOD also has organic-hemp CBD oil operations in Canada and through its wholly owned subsidiary HemPoland, which distributes premium-hemp CBD oil in the EU. The company grows high-quality, organic cannabis with sustainable, all-natural principles. TGOD’s products are laboratory tested to ensure patients have access to a standardized, safe and consistent product. TGOD has a planned capacity of 219,000 kgs and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. For more information, visit the company’s website at www.TGOD.ca.

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF 

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Pressure BioSciences Inc. (PBIO) Receives Two New Purchase Orders for Revolutionary BaroShear K45 Processing System

Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced its receipt of two additional purchase orders for its revolutionary BaroShear(TM) K45 processing system. According to the update, the BaroShear K45, based on the company’s proprietary Ultra Shear Technology(TM) (“UST”) platform, is a unique and powerful nanoemulsification system designed to resolve one of the CBD industry’s most critical problems: the extremely poor solubility of CBD Oil in water. “We fully appreciate both the challenges and the significant emerging market opportunity of having the ability to deliver CBD in a form that allows for greater absorption and enhanced bioavailability,” NanoPeak Solutions, Inc. President Bruce Leitch said in the news release. “Multiple scientific studies have indicated that CBD should be processed via nanoemulsion technology in order to be truly water soluble and resulting in consumer products possessing both shelf stability and consistent dosages. NanoPeak has spent significant time reviewing and assessing various nanoemulsification platforms and the Company has great confidence that PBI’s BaroShear K45 System will be instrumental in NanoPeak having the ability to offer the highest quality ingredients to be utilized in CBD products of all types.”

To view the full press release, visit http://ibn.fm/vCcwx

About Pressure BioSciences Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Commercial Launch of ChrgD+

Biotechnology company and global drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP)today announced the commercial launch of ChrgD+, the industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format and empowered with DehydraTECH(TM) for fast, effective delivery. ChrgD+ is available online, now for sale to US consumers at ChrgD.life. Lexaria’s technology delivers patented processes within every ChrgD+ serving to improve the consumer experience of hemp oil with CBD. ChrgD+ is formulated with the highest quality multi-spectrum hemp oil ingredients and does NOT use CBD isolates that deprive consumers of the synergistic benefits of multi-spectrum oils. In addition, ChrgD+ relies on the proven technological prowess of DehydraTECH(TM) to gently remove unpleasant flavors rather than using artificial flavors or sweeteners to mask the strong flavors and aromas natural within hemp oil.

To view the full press release, visit http://ibn.fm/1X3of

About Lexaria Bioscience Corp.

Lexaria Bioscience has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and in Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Applies for Nasdaq Listing, Announces Quarterly Highlights

• The Green Organic Dutchman has applied for listing of its common shares on the Nasdaq
• The company announced quarterly and half-yearly financial and operational results for the periods ended June 30, 2019
• Progress of its construction efforts at two sites was included on a list of corporate highlights

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) recently announced that it has applied for a listing of its common shares on the Nasdaq. The listing will require numerous regulatory moves on the part of the company, including registration of the common shares and a confirmation by the Nasdaq that TGOD has met all applicable listing requirements.

“This is an important step in the growth of TGOD, one that will broaden our investor base and increase access for international investors as we build the leading global organic cannabis brand,” TGOD CEO Brian Athaide stated in a news release (http://ibn.fm/JX1Ky). “Our team remains focused on executing our business plan and creating value for our shareholders.”

In addition to its Nasdaq application, TGOD announced its financial and operational results for the period ended June 30, 2019 (http://ibn.fm/9IIRc). “Q2 was pivotal for the company as we began commercial production in the second phase of our Hamilton site and expanded our product line for the Grower’s Circle,” Athaide continued.

Highlights of the company’s operations and performance during the quarter included the following:

• Construction of the company’s Hamilton site and phase 1 at its Valleyfield site are nearing completion. The investment value reached $53.1 million in the second quarter of 2019, with total investments for the year amounting to $100.9 million.
• TGOD achieved a revenue increase of 20 percent over the prior quarter, with revenues amounting to $2.9 million and stemming primarily from the European markets. The company reported a net loss of $16.6 million for Q2 2019 but continues to maintain fiscally responsible practices.
• The company launched its Grower’s Circle project in Canada, which is currently testing the company’s sales and distribution capabilities.

Athaide commented on his team’s commitment to executing its “ambitious” business plan, realizing double digit quarterly growth in Europe and nearing the end of its construction project in Canada. “The product quality feedback from Grower’s Circle has been overwhelmingly positive, confirming that patients appreciate having access to premium certified organic cannabis, an underserved segment of the market,” Athaide added (http://ibn.fm/rjzBY). “We now have our first purchase order from the OCS in hand and look forward to shipping our first recreational sales this week.”

The Green Organic Dutchman produces organic, pesticide-free cannabis using crafting techniques in farming. The company envisions becoming a global leader in providing premium-quality cannabis products that improve the lives of its customers. The company currently conducts operations in the medical cannabis markets of Canada, Europe, the Caribbean and Latin America.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html